Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Novavax, Inc.
Abionic CEO Nicolas Durand explains how Abionic is filling unmet needs in diagnostics and the Swiss company’s plans for expansion.
Coronavirus Notebook: EMA Begins Assessing AZ’s Evusheld, Apeiron Starts Phase I Trial Of Inhaled APN01
The UK has explained its strategy for administering COVID-19 vaccines to people who have been partially immunized abroad.
US FDA can’t say whether it will have its vaccine advisors vote on the heterologous uses of booster doses at its 14-15 October meeting of the Vaccines and Related Biological Products Advisory Committee because it is still reviewing the data. The Agency does not appear to need a formal company application or emergency use authorization amendment to allow this type of boosting.
Coronavirus Notebook: Australia ‘Recognizes’ Unapproved Vaccines, Russia Bigs Up Sputnik’s Chances At WHO
England’s NICE has given its backing to the use of Regeneron’s Ronapreve, and the UK’s new health security body is now fully up and running.
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- CPL Biologicals Pvt. Ltd. (Joint Venture with Cadila)
- Isconova AB
- Novavax AB